Cargando…
Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA)
BACKGROUND: Reduction of cyclin-dependent kinase inhibitor 2A (CDKN2A) (p16 and p14) expression through DNA methylation has been reported in prostate cancer (PCa). This meta-analysis was conducted to assess the difference of p16 and p14 methylation between PCa and different histological types of non...
Autores principales: | Cao, Zipei, Wei, Lijuan, Zhu, Weizhi, Yao, Xuping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895353/ https://www.ncbi.nlm.nih.gov/pubmed/29561434 http://dx.doi.org/10.1097/MD.0000000000010182 |
Ejemplares similares
-
CDKN2B Methylation Correlates with Survival in AML Patients
por: Kamali Dolatabadi, Esmat, et al.
Publicado: (2017) -
Effect of magnesium sulfate on renal colic pain: A PRISMA-compliant meta-analysis
por: Chen, Liang-Fu, et al.
Publicado: (2020) -
Relationship between premature ejaculation and depression: A PRISMA-compliant systematic review and meta-analysis
por: Xia, Yue, et al.
Publicado: (2016) -
PRISMA-combined α-blockers and antimuscarinics for ureteral stent-related symptoms: A meta-analysis
por: Zhang, Yu-ming, et al.
Publicado: (2017) -
Kidney stones may increase the risk of coronary heart disease and stroke: A PRISMA-Compliant meta-analysis
por: Peng, Jian-Ping, et al.
Publicado: (2017)